The organocatalytic three-step total synthesis of (+)-frondosin BElectronic supplementary information (ESI) available: Experimental procedures and spectral data for all new compounds; interview with David MacMillan. See DOI: 10.1039/c0sc00204f
The frondosins are a family of marine sesquiterpenes isolated from the sponge Dysidea frondosa that exhibit biological activities ranging from anti-inflammatory properties to potential application in anticancer and HIV therapy. Herein, a concise enantioselective total synthesis of (+)-frondosin B is...
Saved in:
Main Authors | , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
07.06.2010
|
Online Access | Get full text |
Cover
Loading…
Summary: | The frondosins are a family of marine sesquiterpenes isolated from the sponge
Dysidea frondosa
that exhibit biological activities ranging from anti-inflammatory properties to potential application in anticancer and HIV therapy. Herein, a concise enantioselective total synthesis of (+)-frondosin B is described which requires a total of three chemical steps. The enantioselective conjugate addition of a benzofuran-derived boronic acid to crotonaldehyde in the presence of an imidazolidinone organocatalyst builds the critical stereogenic center of frondosin B in the first operation, while the remaining two ring systems of this natural product are installed in the two subsequent steps. A combination of X-ray crystallographic data, deuterium labeling, and chemical correlation studies provides further evidence as to the correct absolute stereochemical assignment of (+)-frondosin B.
A concise enantioselective total synthesis of (+)-frondosin B is described which requires a total of three chemical steps. X-Ray crystallographic data, deuterium labeling, and chemical correlation studies provide evidence as to the correct absolute stereochemical assignment of (+)-frondosin B. |
---|---|
Bibliography: | Electronic supplementary information (ESI) available: Experimental procedures and spectral data for all new compounds; interview with David MacMillan. See DOI 10.1039/c0sc00204f |
ISSN: | 2041-6520 2041-6539 |
DOI: | 10.1039/c0sc00204f |